A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 225M | 225M | 187M | 159M | 139M | 127M |
| Net Income | -16M | -16M | -10.0M | -22M | -29M | -27M |
| EPS | $-0.34 | $-0.34 | $-0.23 | $-0.51 | $-0.69 | $-0.65 |
| Free Cash Flow | -2.9M | -2.9M | 1.4M | -20M | -36M | -41M |
| ROIC | -4.4% | -9.6% | -2.8% | -15.3% | -19.7% | -17.3% |
| Gross Margin | 74.3% | 74.3% | 75.8% | 76.6% | 82.6% | 82.0% |
| Debt/Equity | 0.38 | 0.38 | 0.46 | 0.49 | 0.45 | 0.60 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -7.8M | -7.8M | -3.3M | -21M | -30M | -25M |
| Operating Margin | -3.5% | -3.5% | -1.8% | -13.5% | -21.4% | -20.0% |
| ROE | -12.2% | -13.5% | -9.6% | -22.7% | -28.7% | -22.9% |
| Shares Outstanding | 46M | 46M | 43M | 43M | 42M | 42M |
Axogen, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 78.3%.
Axogen, Inc. (AXGN) has a 5-year average return on invested capital (ROIC) of -12.9%. This is below average and may indicate limited pricing power.
Axogen, Inc. (AXGN) has a market capitalization of $1.6B. It is classified as a small-cap stock.
Axogen, Inc. (AXGN) does not currently pay a regular dividend.
Axogen, Inc. (AXGN) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Axogen, Inc. (AXGN) reported annual revenue of $225 million in its most recent fiscal year, based on SEC EDGAR filings.
Axogen, Inc. (AXGN) has a net profit margin of -7.0%. The company is currently unprofitable.
Axogen, Inc. (AXGN) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Axogen, Inc. (AXGN) has a debt-to-equity ratio of 0.38. This indicates a conservatively financed balance sheet.
Axogen, Inc. (AXGN) reported earnings per share (EPS) of $-0.34 in its most recent fiscal year.
Axogen, Inc. (AXGN) has a return on equity (ROE) of -13.5%. A negative ROE may indicate losses or negative equity.
Axogen, Inc. (AXGN) has a 5-year average gross margin of 78.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Axogen, Inc. (AXGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Axogen, Inc. (AXGN) has a book value per share of $2.79, based on its most recent annual SEC filing.